Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: George Frey/AFP via Getty Images

Oklahoma has secured a $2.6 million refund for a malaria drug purchase once touted by former President Trump as a treatment for COVID-19, the state's attorney general announced Friday.

Why it matters: Trump repeatedly promoted hydroxychloroquine last year despite health officials warning that the drug should not be prescribed for treating COVID-19 outside of research or hospital settings due to serious side effects. Oklahoma purchased 1.2 million hydroxychloroquine pills in April 2020, per AP.

What they're saying: Attorney General Mike Hunter said the state reached an agreement with FFF Enterprises, a private medical supplier.

  • "They recognized we were in competition with every other state in the nation to get whatever we could to protect Oklahomans. When it was determined the drug wasn’t effective in combatting the virus, they did the right thing by refunding our money," he said in a statement.
  • The state will return its stockpile and receive the purchase price in full.

Go deeper

May 7, 2021 - Health

WHO authorizes China's Sinopharm COVID-19 vaccine for emergency use

A medical worker administering a coronavirus vaccine in Nanjing, China, on May 7, 2021. Photo: Costfoto/Barcroft Media via Getty Images

The World Health Organization authorized China’s Sinopharm’s COVID-19 vaccine for emergency use on Friday, making it the sixth vaccine to receive clearance from the global health agency.

Why it matters: The authorization will allow COVAX, the WHO's initiative to equitably develop and distribute coronavirus vaccines, to purchase Sinopharm's vaccine and bolster its supply, according to the New York Times.

May 7, 2021 - Health

Pfizer begins application for full FDA approval of COVID-19 vaccine

Photo: Christof Stache/AFP via Getty Images

Pfizer and BioNTech announced Friday that they have initiated the process of applying for full FDA approval of their COVID-19 vaccine for people 16 and older.

Why it matters: It's the first coronavirus vaccine to seek a Biologics License Application (BLA), which requires at least six months of data, according to CNBC.